Nasopharyngeal carcinoma treated by radical radiotherapy alone: Ten-year experience of a single institution

被引:382
作者
Yi, Jun-Lin [1 ]
Gao, Li [1 ]
Huang, Xiao-Dong [1 ]
Li, Su-Yan [1 ]
Luo, Jin-Wei [1 ]
Cai, Wei-Ming [1 ]
Xiao, Jian-Ping [1 ]
Xu, Guo-Zhen [1 ]
机构
[1] Canc Hosp, Dept Radiat Oncol, Chinese Acad Med Sci, Peking Union Med Coll, Beijing 100021, Peoples R China
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2006年 / 65卷 / 01期
关键词
nasopharyngeal carcinoma; radiotherapy; prognosis; failure pattern;
D O I
10.1016/j.ijrobp.2005.12.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: To report on our experience in the treatment of nasopharyngeal carcinoma (NPC) by radical radiotherapy alone in our institution during the last decade. Methods and Materials: From January 1990 to May 1999, 905 NPC patients were treated and were studied retrospectively. Radical radiotherapy was given to this cohort by conventional technique in a routine dose of 70-72 Gy to the primary tumor and metastatic lymph nodes. In case of residual primary lesion, a boost dose of 8-24 Gy was delivered by either Ir-192 afterloading brachytherapy, fractionated stereotactic radiotherapy, conformal radiotherapy, or small external-beam fields. Results: The 5-year and 10-year local-regional control, overall survival, and disease-free survival rates were 81.7% and 76.7%, 76.1% and 66.5%, 58.4% and 52.1%, respectively. In case of residual primary lesions after a dose of 70-72 Gy of conventional external-beam radiotherapy (EBRT), an additional boost was able to achieve a local control of 80.8%, similar to that obtained with primary lesions that completely disappeared at 70-72 Gy (82.6%, p=0.892). Conclusions: The treatment results of radical EBRT followed by a boost dose to the residual primary tumor for nasopharyngeal carcinoma in our institution are promising. (c) 2006 Elsevier Inc.
引用
收藏
页码:161 / 168
页数:8
相关论文
共 38 条
[1]
Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer [J].
Adelstein, DJ ;
Li, Y ;
Adams, GL ;
Wagner, H ;
Kish, JA ;
Ensley, JF ;
Schuller, DE ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :92-98
[2]
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099 [J].
Al-Sarraf, M ;
LeBlanc, M ;
Giri, PGS ;
Fu, KK ;
Cooper, J ;
Vuong, T ;
Forastiere, AA ;
Adams, G ;
Sakr, WA ;
Schuller, DE ;
Ensley, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1310-1317
[3]
Using technology to decrease xerostomia for head and neck cancer patients treated with radiation therapy [J].
Amosson, CM ;
Teh, BS ;
Mai, WY ;
Woo, SY ;
Chiu, JK ;
Donovan, DT ;
Parke, R ;
Carpenter, LS ;
Lu, HH ;
Grant, WH ;
Butler, EB .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :71-79
[4]
Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the SMART (simultaneous modulated accelerated radiation therapy) boost technique [J].
Amosson, CM ;
Teh, BS ;
Van, TJ ;
Uy, N ;
Huang, E ;
Mai, WY ;
Frolov, A ;
Woo, SY ;
Chiu, JK ;
Carpenter, LS ;
Lu, HH ;
Grant, WH ;
Butler, EB .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (01) :136-144
[5]
Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome [J].
Brizel, DM ;
Dodge, RK ;
Clough, RW ;
Dewhirst, MW .
RADIOTHERAPY AND ONCOLOGY, 1999, 53 (02) :113-117
[6]
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: Final results of the radiotherapy cooperative clinical trials group of the German cancer society 95-06 prospective randomized trial [J].
Budach, V ;
Stuschke, M ;
Budach, W ;
Baumann, M ;
Geismar, D ;
Grabenbauer, G ;
Lammert, I ;
Jahnke, K ;
Stueben, G ;
Herrmann, T ;
Bamberg, M ;
Wust, P ;
Hinkelbein, W ;
Wernecke, KD .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1125-1135
[7]
Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: Impact on future clinical trials [J].
Cheng, SH ;
Yen, KL ;
Jian, JJM ;
Tsai, SYC ;
Chu, NM ;
Leu, SY ;
Chan, KY ;
Tan, TD ;
Cheng, JC ;
Hsieh, CY ;
Huang, AT .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (03) :717-726
[8]
Radiotherapy alone in patients with advanced nasopharyngeal cancer: comparison with an intergroup study - Is combined modality treatment really necessary? [J].
Chow, E ;
Payne, D ;
O'Sullivan, B ;
Pintilie, M ;
Liu, FF ;
Waldron, J ;
Warde, P ;
Cummings, B .
RADIOTHERAPY AND ONCOLOGY, 2002, 63 (03) :269-274
[9]
Treatment outcome after radiotherapy alone for patients with stage I-II nasopharyngeal carcinoma [J].
Chua, DTT ;
Sham, JST ;
Kwong, DLW ;
Au, GKH .
CANCER, 2003, 98 (01) :74-80
[10]
Chua DTT, 2001, CANCER-AM CANCER SOC, V92, P2845, DOI 10.1002/1097-0142(20011201)92:11<2845::AID-CNCR10133>3.0.CO